Latest Breaking News On - Ezra rosen - Page 1 : comparemela.com

EFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients

Median progression free survival of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients Zotatifin generally.

San antonioUnited statesKevin gardnerChristopherm calabreseEzra rosenMike tattorySteve worlandLifesci communicationsMemorial sloan kettering cancer centerEarly drug development specialistExchange commissionEffector therapeutics incMedical oncologistAntonio breast cancer symposiumPrivate securities litigation reform act

eFFECTOR Therapeutics (EFTR) Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients

eFFECTOR Therapeutics (EFTR) Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan antonioEzra rosenSteve worlandEffector therapeutics incMemorial sloan kettering cancer centerEarly drug development specialistMedical oncologistAntonio breast cancer symposium

eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients

eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan antonioEzra rosenSteve worlandChristopherm calabreseMike tattoryKevin gardnerEarly drug development specialistEffector therapeutics incExchange commissionMemorial sloan kettering cancer centerLifesci communicationsMedical oncologistAntonio breast cancer symposiumPrivate securities litigation reform act

Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer

Ezra Rosen, MD, PhD, highlights the early-phase investigation of zotatifin in estrogen receptor-positive metastatic breast cancer, explains the agent’s unique mechanism of action as well as its efficacy and safety in a heavily pretreated population, and underscores the need for improved sequencing of the myriad of treatment options in the post–CDK4/6 inhibitor space.

Memorial sloan kettering cancer centerNew yorkUnited statesEzra rosenBreast cancer

Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Repare Therapeutics Inc. , a leading clinical-stage precision oncology company, today announced it will present initial data from Module 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial in a.

United statesMemorial sloan kettering cancer centerNew yorkDavid galloMichael zimmermanEzra rosenTimothya yapElia aguado fraileInternational conference on molecularUniversity of texas md anderson cancer centerCompany nasdaqRepare therapeutics incRepare therapeuticsMolecular targetsCancer therapeuticsCancer center